niceritrol and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

niceritrol has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arakawa, K; Kobori, S; Kono, S; Matsunaga, A; Sakai, T; Sasaki, J; Sato, Y; Setoguchi, Y; Shichiri, M; Yamamoto, K	1

Trials

1 trial(s) available for niceritrol and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

Article	Year
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. International journal of clinical pharmacology and therapeutics, 1995, Volume: 33, Issue:7 Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipase; Lipids; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Niceritrol	1995

Article

Year

Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.

International journal of clinical pharmacology and therapeutics, 1995, Volume: 33, Issue:7

Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipase; Lipids; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Niceritrol

1995